TY  - JOUR

T1  - Laboratory safety from a randomized 16-week phase III study of dupilumab in children aged 6 months to 5 years with moderate-to-severe atopic dermatitis

JO  - Pediatric Drugs

PY  - 2022/12/19

AU  - Paller AS

AU  - Siegfried EC

AU  - Cork MJ

AU  - Wollenberg A

AU  - Arkwright PD

AU  - Gonzalez ME

AU  - Lockshin B

AU  - Chen Z

AU  - Bansal A

AU  - Levit NA

AU  - Prescilla R

ED  - 

DO  - DOI: 10.1007/s40272-022-00553-8

PB  - Springer Science and Business Media LLC

VL  - 25

SP  - 67

EP  - 77

Y2  - 2024/12/22

ER  -